Evaluation of Bicytopenia

Initial Laboratory Assessment

The National Comprehensive Cancer Network recommends beginning with a complete blood count with differential, peripheral blood smear review, and reticulocyte count to characterize the cytopenias, followed by bone marrow aspiration and biopsy if initial workup suggests a primary bone marrow disorder or if the etiology remains unclear after excluding common reversible causes 1, 2, 3
A complete blood count (CBC) with differential and reticulocyte count is essential to confirm bicytopenia and assess bone marrow response 1, 2, 3
Peripheral blood smear review by an experienced hematopathologist is necessary to evaluate cell morphology, dysplasia, and identify abnormal cells 1, 2, 3
The reticulocyte index (RI) helps distinguish decreased production (RI <1.0-2.0) from increased destruction or loss 1

The duration and tempo of cytopenias are crucial, as stable cytopenias for at least 6 months suggest myelodysplastic syndrome (MDS), while rapid progression may indicate acute leukemia 2, 3
Medication exposure, including antibiotics, anti-HCV drugs, and chemotherapy agents, should be assessed 4
Nutritional history, focusing on vitamin B12, folate intake, and alcohol consumption, is essential 1, 4
Infectious exposures, such as recent viral illness, HIV, hepatitis B/C, and CMV, should be evaluated 1, 4

Vitamin B12 and RBC folate levels should be measured, as macrocytic anemia (MCV >100 fL) suggests a megaloblastic process 1, 2, 3
Iron studies, including serum iron, TIBC, and ferritin, help identify absolute iron deficiency 1
Serum erythropoietin level should be assessed 2, 3
HIV, hepatitis B, hepatitis C, and H. pylori testing are necessary, particularly in new thrombocytopenia 4
CMV screening should be performed if lymphopenia is present 4

Bone marrow aspiration and biopsy should be performed simultaneously when abnormalities are detected on peripheral smear, or when unexplained persistent bicytopenia is present after excluding reversible causes 2, 3
Morphologic evaluation with assessment of dysplasia in all three lineages is essential, as ≥10% dysplasia in ≥1 lineage suggests MDS 2, 3
Prussian blue stain for iron helps identify ring sideroblasts (≥15% indicates sideroblastic features) 2, 3, 6
Blast percentage by morphology should be assessed, as 5-19% blasts indicates MDS with excess blasts 2, 3

Pancytopenia with sideroblastic features should be classified as MDS-unclassified (MDS-U) rather than simple sideroblastic anemia, indicating a worse prognosis and higher risk of progression to acute myeloid leukemia 6
Over 90% of hematologic malignancies present with cytopenias, with bicytopenia and pancytopenia together constituting 58% of presentations 4
Acute leukemia is the most common malignancy, with 97% presenting with cytopenia 4
Lymphadenopathy, splenomegaly, and hepatomegaly are most significantly associated with malignancies (p<0.001) 5

Do not rely on flow cytometry blast percentage for prognostic assessment - morphologic evaluation by an experienced hematopathologist is essential 2, 3
Do not diagnose simple sideroblastic anemia if pancytopenia is present - this indicates MDS-U with a worse prognosis 6
Do not delay bone marrow evaluation if peripheral smear shows dysplasia or if cytopenias are unexplained after initial workup 2, 3
Perform bone marrow aspiration AND biopsy simultaneously - they are complementary and both necessary for complete evaluation 2, 3
Screen for PNH and HLA-DR15 in young patients with hypoplastic bone marrow as they may respond to immunosuppressive therapy 2, 3